Accession Number

Recombinant human growth hormone (somatotropin) 191 residues, MW 22.1 kD, synthesized in E. coli

Approved, Investigational
Biologic Classification
Protein Based Therapies
Protein Structure
Protein Chemical Formula
Protein Average Weight
22129.0 Da
>DB00052 sequence
Download FASTA Format
  • Growth hormone
  • Growth hormone (human)
  • hGH
  • Human growth hormone
  • Recombinant human growth hormone
  • rhGH
  • Somatotropin (human)
  • Somatotropin human
  • Somatotropin human growth hormone
  • Somatropin
  • Somatropin (rDNA origin)
  • Somatropin (recombinant DNA origin)
  • Somatropin [rDNA origin]
  • Somatropin recombinant
  • Somatropin(recombinant DNA origin)
  • Somatropina
External IDs
  • CB-311
  • DA-3002
  • LY-137998
  • LY137998



For treatment of dwarfism, acromegaly and prevention of HIV-induced weight loss

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More

Used in the treatment of dwarfism and growth failure, growth hormone (hGH) stimulates skeletal growth in pediatric patients with growth failure due to a lack of adequate secretion of endogenous GH. Skeletal growth is accomplished at the epiphyseal plates at the ends of a growing bone. Growth and metabolism of epiphyseal plate cells are directly stimulated by GH and one of its mediators, IGF-I (insulin-like growth factor).

Mechanism of action

hGH binds to the human growth hormone receptor (GHR). Upon binding, hGH causes dimerization of GHR, activation of the GHR-associated JAK2 tyrosine kinase, and tyrosyl phosphorylation of both JAK2 and GHR. These events recruit and/or activate a variety of signaling molecules, including MAP kinases, insulin receptor substrates, phosphatidylinositol 3' phosphate kinase, diacylglycerol, protein kinase C, intracellular calcium, and Stat transcription factors. These signaling molecules contribute to the GH-induced changes in enzymatic activity, transport function, and gene expression that ultimately culminate in changes in growth and metabolism.

AGrowth hormone receptor
AProlactin receptorNot AvailableHumans
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Not Available
Route of elimination

Although calcium excretion in the urine is increased, there is a simultaneous increase in calcium absorption from the intestine. Somatropin stimulates the synthesis of chondroitin sulfate and collagen, and increases the urinary excretion of hydroxyproline.

Not Available
  • 2.3 +/- 1.8 mL/min/kg [GHD patients (IV 33 ng/kg/min)]
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Not Available
Affected organisms
  • Humans and other mammals
Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
AcipimoxThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Acipimox.
Alendronic acidThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Alendronic acid.
AmiodaroneThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Amiodarone.
Amphotericin BThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Amphotericin B.
AtorvastatinThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Atorvastatin.
BaclofenThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Baclofen.
Beclomethasone dipropionateThe therapeutic efficacy of Somatotropin can be decreased when used in combination with Beclomethasone dipropionate.
BetamethasoneThe therapeutic efficacy of Betamethasone can be decreased when used in combination with Somatotropin.
Betamethasone phosphateThe therapeutic efficacy of Somatotropin can be decreased when used in combination with Betamethasone phosphate.
BezafibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Bezafibrate.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available


International/Other Brands
BioTropin (Biotech General)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
GenotropinPowder, for solution0.6 mgSubcutaneousPfizer Canada Ulc2013-09-18Not applicableCanada flag
Genotropin1.8 mg/0.25mLSubcutaneousPharmacia and Upjohn Company LLC1995-12-20Not applicableUS flag
Genotropin1.2 mg/0.25mLSubcutaneousPharmacia and Upjohn Company LLC1995-12-20Not applicableUS flag
GenotropinPowder, for solution5 mgSubcutaneousPfizer Canada UlcNot applicableNot applicableCanada flag
GenotropinPowder, for solution1.6 mgSubcutaneousPfizer Canada Ulc2013-09-18Not applicableCanada flag
GenotropinKit0.6 mg/0.25mLSubcutaneousPharmacia and Upjohn Company LLC1995-12-20Not applicableUS flag
GenotropinPowder, for solution1 mgSubcutaneousPfizer Canada Ulc2013-09-18Not applicableCanada flag
Genotropin12 mg/1mLSubcutaneousPharmacia and Upjohn Company LLC1995-12-20Not applicableUS flag
GenotropinKit0.4 mg/0.25mLSubcutaneousPhysicians Total Care, Inc.2006-06-302012-06-30US flag
GenotropinPowder, for solution12 mgSubcutaneousPfizer Canada Ulc2013-09-18Not applicableCanada flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Bio-tropinSomatotropin (4.8 mg) + Sodium chloride (10 ml)Liquid; Powder, for solutionSubcutaneousNovopharm LimitedNot applicableNot applicableCanada flag
Bio-tropinSomatotropin (1.8 mg) + Sodium chloride (10 ml)Liquid; Powder, for solutionSubcutaneousNovopharm LimitedNot applicableNot applicableCanada flag
HumatropeSomatotropin (6 mg)Liquid; Powder, for solutionIntramuscular; SubcutaneousEli Lilly & Co. Ltd.2001-09-25Not applicableCanada flag
HumatropeSomatotropin (24 mg)Liquid; Powder, for solutionIntramuscular; SubcutaneousEli Lilly & Co. Ltd.2003-12-08Not applicableCanada flag
HumatropeSomatotropin (12 mg)Liquid; Powder, for solutionIntramuscular; SubcutaneousEli Lilly & Co. Ltd.2001-08-28Not applicableCanada flag
Nutropin - Kit Pws(10mg) & Liq(10ml) Im ScSomatotropin (10 mg) + Water (10 ml)Kit; Powder, for solutionIntramuscular; SubcutaneousHoffmann La Roche2002-10-082013-12-02Canada flag
Nutropin - Kit Pws(5mg) & Liq(10ml) Im ScSomatotropin (5 mg) + Water (10 ml)Kit; Powder, for solutionIntramuscular; SubcutaneousHoffmann La Roche1997-01-202011-07-19Canada flag
OmnitropeSomatotropin (5.8 mg) + Water (1.14 ml)Kit; Powder, for solutionSubcutaneousSandoz Canada IncorporatedNot applicableNot applicableCanada flag
Saizen 10iu - KitSomatotropin (3.3 mg) + Sodium chloride (5 ml)Powder, for solutionIntramuscular; SubcutaneousEmd Serono, A Division Of Emd Inc., Canada1996-10-172019-02-21Canada flag
SerostimSomatotropin (5 mg) + Water (1 ml)Powder, for solutionSubcutaneousEmd Serono, A Division Of Emd Inc., Canada1999-07-28Not applicableCanada flag


ATC Codes
H01AC01 — Somatropin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Not Available
Organic Compounds
Super Class
Organic Acids
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Alternative Parents
Not Available
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

CAS number


Synthesis Reference

Mandayam J. Narasimhan, John A. Anderson, "Process for the large scale production of human growth hormone by serial secondary suspension culture." U.S. Patent US4124448, issued January, 1963.

General References
  1. Seltzer V, Tonge SR: Proceedings: Methylamphetamine withdrawal as a model for the depressive state: antagonism of post-amphetamine depression by imipramine. J Pharm Pharmacol. 1975 Dec;27 Suppl?-2:16P. [PubMed:2688]
  2. Alba-Roth J, Muller OA, Schopohl J, von Werder K: Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion. J Clin Endocrinol Metab. 1988 Dec;67(6):1186-9. [PubMed:2903866]
  3. Scarth JP: Modulation of the growth hormone-insulin-like growth factor (GH-IGF) axis by pharmaceutical, nutraceutical and environmental xenobiotics: an emerging role for xenobiotic-metabolizing enzymes and the transcription factors regulating their expression. A review. Xenobiotica. 2006 Feb-Mar;36(2-3):119-218. [PubMed:16702112]
  4. Takahashi Y, Kipnis DM, Daughaday WH: Growth hormone secretion during sleep. J Clin Invest. 1968 Sep;47(9):2079-90. [PubMed:5675428]
PubChem Substance
Therapeutic Targets Database
RxList Drug Page Drug Page
AHFS Codes
  • 68:28.00 — Pituitary
  • 68:30.04 — Somatotropin Agonists*
FDA label
Download (241 KB)

Clinical Trials

Clinical Trials
4Active Not RecruitingTreatmentIdiopathic Short Stature (ISS)1
4Active Not RecruitingTreatmentInfertility1
4Active Not RecruitingTreatmentSmall for Gestational Age1
4CompletedBasic ScienceHuman Growth Hormone Deficiency1
4CompletedDiagnosticChronic Renal Failure (CRF) / Human Growth Hormone Deficiency1
4CompletedPreventionHealthy Volunteers1
4CompletedTreatmentAdult Onset Growth Hormone Deficiency1
4CompletedTreatmentAdult Onset Growth Hormone Deficiency / Growth Hormone Disorders1
4CompletedTreatmentBMI >30 kg/m21
4CompletedTreatmentBMI >30 kg/m2 / Impaired Glucose Tolerance / Metabolic Syndromes1


  • Genentech inc
  • Serono laboratories inc
  • Cangene corp
  • Ferring pharmaceuticals inc
  • Pharmacia and upjohn co
  • Eli lilly and co
  • Novo nordisk inc
  • Sandoz inc
  • Emd serono inc
  • Lg life sciences ltd
  • Bio Technology General Ltd.
  • Bristol-Myers Squibb Co.
  • BTG Pharmaceuticals Corp.
  • Ebewe Pharma
  • Eli Lilly & Co.
  • EMD Canada Inc.
  • F Hoffmann-La Roche Ltd.
  • First KJM Corporation
  • Gate Pharmaceuticals
  • Genentech Inc.
  • Hospira Inc.
  • Merck KGaA
  • Merck Serono SPA
  • Novartis AG
  • Novo Nordisk Inc.
  • Pfizer Inc.
  • Pharmacia Inc.
  • Physicians Total Care Inc.
  • Sandoz
  • Serono SA
  • Vetter Pharma Fertigung GmbH and Co. KG
  • Wasserburger Arzneimittelwerk GmbH
Dosage Forms
Powder4 MG
Liquid; powder, for solutionSubcutaneous
Injection, powder, for solution1.6 mg
Injection, powder, for solution4 iu
Injection, powder, for solution12 mg
Injection, powder, for solution5.3 mg
Injection, powder, for solutionParenteral0.4 MG
Injection, powder, for solutionParenteral0.6 MG
Injection, powder, for solutionParenteral0.8 MG
Injection, powder, for solutionParenteral1 MG
Injection, powder, for solutionParenteral1.2 MG
Injection, powder, for solutionParenteral1.4 MG
Injection, powder, for solutionParenteral1.6 MG
Injection, powder, for solutionParenteral1.8 MG
Injection, powder, for solutionParenteral2 MG
Injection, powder, for solutionSubcutaneous3 IU
Injection, powder, for solutionSubcutaneous4 IU
Injection, powder, for solutionSubcutaneous5 mg
KitSubcutaneous0.2 mg/0.25mL
KitSubcutaneous0.4 mg/0.25mL
KitSubcutaneous0.6 mg/0.25mL
KitSubcutaneous0.8 mg/0.25mL
Powder, for solutionSubcutaneous0.2 mg
Powder, for solutionSubcutaneous0.4 mg
Powder, for solutionSubcutaneous0.6 mg
Powder, for solutionSubcutaneous0.8 mg
Powder, for solutionSubcutaneous1 mg
Powder, for solutionSubcutaneous1.2 mg
Powder, for solutionSubcutaneous1.4 mg
Powder, for solutionSubcutaneous1.6 mg
Powder, for solutionSubcutaneous1.8 mg
Powder, for solutionSubcutaneous12 mg
Powder, for solutionSubcutaneous2 mg
Powder, for solutionSubcutaneous5 mg
Powder, for solutionSubcutaneous5.3 mg
Injection, powder, lyophilized, for solutionSubcutaneous12 mg
Injection, powder, for solutionParenteral12 mg
InjectionSubcutaneous16 iu
InjectionSubcutaneous36 iu
Injection, powder, for solutionParenteral5.3 mg
Injection, powder, for solutionParenteral0.2 mg
Injection, powder, for solutionSubcutaneous12 mg
Injection, powder, for solutionSubcutaneous5.3 mg
SolutionIntramuscular; Subcutaneous8 IU
SolutionIntramuscular; Subcutaneous16 IU
Injection, powder, for solution6 mg
Injection, powder, lyophilized, for solutionIntramuscular; Subcutaneous5.33 mg
KitIntramuscular; Subcutaneous12 mg/2.88mL
KitIntramuscular; Subcutaneous24 mg/2.88mL
KitIntramuscular; Subcutaneous5 mg/5mL
KitIntramuscular; Subcutaneous6 mg/2.88mL
Liquid; powder, for solutionIntramuscular; Subcutaneous
InjectionSubcutaneous18 iu
Injection, powder, for solutionParenteral24 mg
Injection, powder, for solutionParenteral6 mg
InjectionSubcutaneous72 iu
Injection, powder, lyophilized, for solutionSubcutaneous8 mg
Injection, solutionSubcutaneous10 mg/1.5mL
Injection, solutionSubcutaneous15 mg/1.5mL
Injection, solutionSubcutaneous30 mg/3mL
Injection, solutionSubcutaneous5 mg/1.5mL
Injection, solutionParenteral10 mg/1.5ml
Injection, solutionParenteral15 mg/1.5ml
Injection, solutionParenteral5 mg/1.5ml
SolutionSubcutaneous6.7 mg
SolutionSubcutaneous10 mg
SolutionSubcutaneous3.3 mg
InjectionSubcutaneous15 mg/1.5ml
Injection, solution10 mg/1.5mL
Injection, solution5 mg/1.5mL
KitSubcutaneous10 mg/10mg
KitSubcutaneous5 mg/5mg
Kit; powder, for solutionIntramuscular; Subcutaneous
Injection, solutionSubcutaneous5 mg/2mL
SolutionSubcutaneous5 mg
Injection, solutionSubcutaneous20 mg/2mL
KitSubcutaneous13.5 mg/1mL
KitSubcutaneous18 mg/1mL
KitSubcutaneous22.5 mg/1mL
Injection, solutionSubcutaneous10 mg/2ml
InjectionSubcutaneous10 mg/1.5ml
InjectionSubcutaneous5 mg/1.5ml
Injection, powder, for solutionSubcutaneous1.3 mg/ml
Injection, powder, for solutionSubcutaneous5 mg/ml
Injection, solutionParenteral; Subcutaneous10 MG/1.5ML
Injection, solutionParenteral; Subcutaneous15 MG/1.5ML
Injection, solutionParenteral; Subcutaneous5 MG/1.5ML
KitSubcutaneous1.5 mg/1.13mL
KitSubcutaneous5.8 mg/1mL
Kit; powder, for solutionSubcutaneous
SolutionSubcutaneous15 mg
Injection, solutionSubcutaneous10 mg
Injection, solutionSubcutaneous15 mg
Injection, solutionSubcutaneous5 mg
Injection, powder, for solutionIntramuscular; Subcutaneous0.67 MG
Injection, powder, for solutionSubcutaneous8 mg
Injection, powder, lyophilized, for solutionIntramuscular; Subcutaneous3.33 MG
Injection, powder, lyophilized, for solutionIntramuscular; Subcutaneous8 MG
KitIntramuscular; Subcutaneous5 mg/3mL
KitIntramuscular; Subcutaneous8.8 mg/3mL
Powder, for solutionIntramuscular; Subcutaneous5 mg
SolutionSubcutaneous5.83 mg
SolutionSubcutaneous8 mg
SolutionSubcutaneous20 mg
Powder, for solutionIntramuscular; Subcutaneous
InjectionSubcutaneous12 mg/1.5ml
InjectionSubcutaneous20 mg/2.5ml
Injection, powder, for solutionSubcutaneous3.33 mg
InjectionSubcutaneous4 IU
InjectionSubcutaneous5.83 mg/ml
Injection, solution5.83 mg/ml
InjectionSubcutaneous6 mg/1.03ml
Injection, powder, for solutionParenteral8 mg
Injection, solution8 mg/ml
Powder, for solutionSubcutaneous
Injection, solutionSubcutaneous8 mg
Injection, powder, for solution8 mg
KitIntramuscular; Subcutaneous8.8 mg/1.51mL
Injection, solution5.83 mg/1mL
Injection, solutionSubcutaneous12 mg
Injection, solutionSubcutaneous20 mg
Injection, solutionSubcutaneous6 mg
Injection, powder, lyophilized, for solutionSubcutaneous1.33 mg
SolutionSubcutaneous6 mg
KitSubcutaneous4 mg/1mL
KitSubcutaneous5 mg/1mL
KitSubcutaneous6 mg/1mL
KitSubcutaneous8.8 mg/2mL
Powder, for solutionSubcutaneous
Injection, powder, lyophilized, for solutionIntramuscular; Subcutaneous1.33 mg
Injection, powder, for suspension, extended releaseSubcutaneous10 MG
Injection, powder, for suspension, extended releaseSubcutaneous2 MG
Injection, powder, for suspension, extended releaseSubcutaneous20 MG
Injection, powder, for suspension, extended releaseSubcutaneous4 MG
Injection, powder, for suspension, extended releaseSubcutaneous7 MG
KitSubcutaneous10 mg/1
KitSubcutaneous10 mg/10mL
KitSubcutaneous5 mg/1
Injection, powder, for solutionSubcutaneous15 mg/1.5ml
Powder1.33 MG
Injection, powder, for solution10 MG/ML
Injection, powder, for solution4 mg
Injection, powder, lyophilized, for solutionSubcutaneous1.3 mg
Injection, powder, lyophilized, for solutionSubcutaneous4 IU
Injection, powder, for solutionParenteral10 mg/ml
Injection, powder, for solutionParenteral4 mg
Injection, powder, lyophilized, for solutionSubcutaneous4 mg
KitSubcutaneous8.8 mg/1mL
Unit descriptionCostUnit
Humatrope 24 mg cartridge1822.9USD cartridge
Norditropin flexpro 15 mg/1.51179.54USD ml
Norditropin 15 mg/1.5ml Solution 1.5ml Cartridge1168.32USD cartridge
Norditropin NordiFlex Pen 15 mg/1.5ml Solution 1 Syringe = 1.5ml1168.32USD pen
Norditropin 15 mg/1.5 ml cartridge1123.38USD ml
Norditropin nordiflx 15 mg/1.51123.38USD ml
Genotropin 12 mg Solution928.36USD each
Humatrope 12 mg cartridge911.45USD cartridge
Nutropin 10 mg vial784.7USD vial
Nutropin aq 20 mg/2ml pen cart759.55USD ml
Nutropin aq nuspin 20 pen cart759.55USD ml
Norditropin NordiFlex Pen 10 mg/1.5ml Solution 1 Syringe = 1.5ml753.86USD pen
Norditropin nordiflex 30 mg/3748.92USD ml
Saizen 8.8 mg Solution Vial626.1USD vial
Saizen Click.Easy 8.8 mg Solution Vial626.1USD vial
Saizen 8.8 mg vial602.02USD vial
Protropin 10 mg Solution Vial549.9USD vial
Humatrope 6 mg cartridge455.72USD cartridge
Genotropin MiniQuick 0.8 mg (7 Cartridges Per Box)433.56USD box
Serostim 8.8 mg vial418.66USD vial
Nutropin 5 mg vial392.35USD vial
Saizen 5 mg Solution Vial391.31USD vial
Genotropin 5.8 mg Cartridge391.21USD cartridge
Norditropin 5 mg/1.5ml Solution 1.5ml Cartridge389.44USD cartridge
Norditropin NordiFlex Pen 5 mg/1.5ml Solution 1 Syringe = 1.5ml389.44USD pen
Saizen 5 mg vial376.26USD vial
Serostim 6 mg vial332.86USD vial
Genotropin MiniQuick 0.6 mg (7 Cartridges Per Box)326.67USD box
Omnitrope 5.8 mg Solution Vial283.38USD vial
Serostim 5 mg vial277.38USD vial
Protropin 5 mg Solution Vial274.95USD vial
Tev-Tropin 5 mg Solution Vial259.45USD vial
Tev-tropin 5 mg vial239.51USD vial
Genotropin MiniQuick 0.4 mg (7 Cartridges Per Box)228.45USD box
Serostim 4 mg vial221.9USD vial
Genotropin MiniQuick 2 mg (7 Cartridges Per Box)154.72USD cartridge
Genotropin miniquick 2 mg150.46USD each
Genotropin miniquick 1.8 mg135.41USD each
Genotropin MiniQuick 1.6 mg (7 Cartridges Per Box)123.78USD cartridge
Genotropin miniquick 1.6 mg120.37USD each
Genotropin MiniQuick 0.2 mg (7 Cartridges Per Box)110.52USD box
Genotropin MiniQuick 1.4 mg (7 Cartridges Per Box)108.78USD cartridge
Genotropin miniquick 1.4 mg105.32USD each
Genotropin MiniQuick 1.2 mg (7 Cartridges Per Box)92.83USD cartridge
Genotropin miniquick 1.2 mg90.28USD each
Genotropin MiniQuick 1 mg (7 Cartridges Per Box)77.36USD cartridge
Genotropin miniquick 1 mg75.23USD each
Genotropin miniquick 0.8 mg60.19USD each
Genotropin miniquick 0.6 mg45.14USD each
Genotropin miniquick 0.4 mg30.09USD each
Genotropin miniquick 0.2 mg15.05USD each
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US5288703No1994-02-222011-10-07US flag
CA2252535No2009-06-232017-04-24Canada flag
CA1326439No1994-01-252011-01-25Canada flag
US6152897No2000-11-282018-11-20US flag
US5898030No1999-04-272016-04-27US flag
US8672898Yes2014-03-182022-07-02US flag
US8684969Yes2014-04-012026-04-20US flag
US9132239Yes2015-09-152032-08-01US flag
US8920383Yes2014-12-302027-01-17US flag
US7686786No2010-03-302026-08-03US flag
US6899699Yes2005-05-312022-07-01US flag
US9108002Yes2015-08-182026-07-26US flag
USRE41956Yes2010-11-232021-07-21US flag
US6004297Yes1999-12-212019-07-28US flag
USRE43834No2012-11-272019-01-28US flag
US5849700No1998-12-152015-12-15US flag
US5849704No1998-12-152015-12-15US flag
US8841252No2014-09-232017-12-26US flag
US6235004No2001-05-222019-01-28US flag
US9486588Yes2016-11-082022-07-02US flag
US9457154Yes2016-10-042028-03-27US flag
USRE46363Yes2017-04-112027-02-03US flag
US9687611Yes2017-06-272027-08-27US flag
US9775953Yes2017-10-032027-01-17US flag
US8579869Yes2013-11-122023-12-30US flag
US7762994Yes2010-07-272024-11-23US flag
US9861757Yes2018-01-092026-07-20US flag
US9616180Yes2017-04-112026-07-20US flag
US10220155Yes2019-03-052027-01-17US flag
US10357616No2019-07-232026-01-20US flag
US10376652No2019-08-132026-01-20US flag
Additional Data Available
  • Filed On
    Filed On
    Available for Purchase

    The date on which a patent was filed with the relevant government.

    Learn more


Experimental Properties
melting point (°C)76 °C at pH 3.5Gomez-Orellana, I. et al., Protein Sci. 7:1352-1358 (1998)
hydrophobicity-0.411Not Available
isoelectric point5.27Not Available


Pharmacological action
General Function
Protein kinase binding
Specific Function
Receptor for pituitary gland growth hormone involved in regulating postnatal body growth. On ligand binding, couples to the JAK2/STAT5 pathway (By similarity).The soluble form (GHBP) acts as a rese...
Gene Name
Uniprot ID
Uniprot Name
Growth hormone receptor
Molecular Weight
71498.885 Da
  1. Walenkamp MJ, Wit JM: Genetic disorders in the growth hormone - insulin-like growth factor-I axis. Horm Res. 2006;66(5):221-30. [PubMed:16917171]
  2. Wu XY, Xu Z, Chen C, Liu FK, Li JS: [Correlation of growth hormone receptor expression to preoperative radiosensitivity of rectal cancer patients]. Ai Zheng. 2006 Sep;25(9):1162-7. [PubMed:16965663]
  3. Adriani M, Garbi C, Amodio G, Russo I, Giovannini M, Amorosi S, Matrecano E, Cosentini E, Candotti F, Pignata C: Functional interaction of common gamma-chain and growth hormone receptor signaling apparatus. J Immunol. 2006 Nov 15;177(10):6889-95. [PubMed:17082603]
  4. Choi JH, Kim HS, Kim SH, Yang YR, Bae YS, Chang JS, Kwon HM, Ryu SH, Suh PG: Phospholipase Cgamma1 negatively regulates growth hormone signalling by forming a ternary complex with Jak2 and protein tyrosine phosphatase-1B. Nat Cell Biol. 2006 Dec;8(12):1389-97. Epub 2006 Nov 26. [PubMed:17128263]
  5. Bernstein RM, Leigh SR, Donovan SM, Monaco MH: Hormones and body size evolution in papionin primates. Am J Phys Anthropol. 2007 Feb;132(2):247-60. [PubMed:17133434]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Pharmacological action
General Function
Protein homodimerization activity
Specific Function
This is a receptor for the anterior pituitary hormone prolactin (PRL). Acts as a prosurvival factor for spermatozoa by inhibiting sperm capacitation through suppression of SRC kinase activation and...
Gene Name
Uniprot ID
Uniprot Name
Prolactin receptor
Molecular Weight
69505.045 Da
  1. Keeler C, Jablonski EM, Albert YB, Taylor BD, Myszka DG, Clevenger CV, Hodsdon ME: The kinetics of binding human prolactin, but not growth hormone, to the prolactin receptor vary over a physiologic pH range. Biochemistry. 2007 Mar 6;46(9):2398-410. Epub 2007 Feb 6. [PubMed:17279774]
  2. Ahmed TA, Buzzelli MD, Lang CH, Capen JB, Shumate ML, Navaratnarajah M, Nagarajan M, Cooney RN: Interleukin-6 inhibits growth hormone-mediated gene expression in hepatocytes. Am J Physiol Gastrointest Liver Physiol. 2007 Jun;292(6):G1793-803. Epub 2007 Mar 29. [PubMed:17395896]
  3. Moderscheim TA, Gorba T, Pathipati P, Kokay IC, Grattan DR, Williams CE, Scheepens A: Prolactin is involved in glial responses following a focal injury to the juvenile rat brain. Neuroscience. 2007 Mar 30;145(3):963-73. Epub 2007 Feb 20. [PubMed:17317019]
  4. Cunningham BC, Bass S, Fuh G, Wells JA: Zinc mediation of the binding of human growth hormone to the human prolactin receptor. Science. 1990 Dec 21;250(4988):1709-12. [PubMed:2270485]

Drug created on June 13, 2005 07:24 / Updated on January 23, 2021 21:03